**Tukavo™ 150 Tablets **

Tukavo™ 150 Tablets contain Tucatinib, a selective HER2 tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine for the treatment of HER2-positive unresectable or metastatic breast cancer. It works by blocking HER2 signaling, helping slow the growth and spread of cancer cells, including in patients with brain metastases.

Effects & Benefits Targets HER2-positive cancer cells to inhibit tumor growth. Used for HER2-positive metastatic or unresectable breast cancer. Effective in combination with trastuzumab and capecitabine. Demonstrates activity against brain metastases. Helps improve progression-free survival. Oral tablet for convenient long-term cancer management under specialist supervision.